July 29, 2015
The Fibrosis-4 score and race were useful in quantifying the risk for end-stage liver disease among patients with both HIV and hepatitis C virus, according to recent findings.
In the retrospective cohort study, researchers evaluated 6,016 HIV/HCV coinfected individuals on ART who were enrolled in the Veterans Aging Cohort Study (VACS) from January 1997 to Sept. 30, 2010. To identify potential predictors of end-stage liver disease (ESLD), the researchers assessed baseline variables such as FIB-4, aspartate aminotransferase-to-platelet ratio index (APRI), BMI, severe anemia, CD4 cell count, HIV RNA greater than 400 copies/mL, alcohol dependence or abuse, diabetes mellitus, hepatitis B coinfection and race among the patients. Study follow-up commenced after 1 year of ART. The primary endpoint was ESLD, which was delineated as hepatic decompensation, hepatocellular carcinoma or liver-associated mortality.